Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 21062242)

1.

Current treatment concepts of Philadelphia-negative MPN.

Wolf D, Rudzki J, Gastl G.

Curr Cancer Drug Targets. 2011 Jan;11(1):44-55. Review.

PMID:
21062242
2.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
3.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
4.

Myeloproliferative neoplasia: a review of clinical criteria and treatment.

Koopmans SM, van Marion AM, Schouten HC.

Neth J Med. 2012 May;70(4):159-67. Review.

5.

Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.

Tefferi A.

Leuk Lymphoma. 2010 Apr;51(4):576-82. doi: 10.3109/10428191003605313. Review.

PMID:
20214447
6.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
7.

JAK2 kinase inhibitors and myeloproliferative disorders.

Chen AT, Prchal JT.

Curr Opin Hematol. 2010 Mar;17(2):110-6. doi: 10.1097/MOH.0b013e3283366b91. Review.

PMID:
20087176
8.

Hemopoiesis in Ph-negative chronic myeloproliferative disorders.

Spanoudakis E, Tsatalas C.

Curr Stem Cell Res Ther. 2009 May;4(2):154-60. Review.

PMID:
19442200
10.

Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.

Tefferi A.

Hematology Am Soc Hematol Educ Program. 2006:240-5. Review.

11.

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Kumar C, Purandare AV, Lee FY, Lorenzi MV.

Oncogene. 2009 Jun 18;28(24):2305-13. doi: 10.1038/onc.2009.107. Epub 2009 May 4. Review.

PMID:
19421140
12.
13.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
14.

Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?

Bock O, Hussein K, Kreipe H.

Curr Stem Cell Res Ther. 2007 Sep;2(3):253-63. Review.

PMID:
18220909
15.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
16.

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Tefferi A, Skoda R, Vardiman JW.

Nat Rev Clin Oncol. 2009 Nov;6(11):627-37. doi: 10.1038/nrclinonc.2009.149. Epub 2009 Oct 6. Review.

PMID:
19806146
17.

Chronic myeloproliferative disorders.

Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M.

Hematology Am Soc Hematol Educ Program. 2003:200-24. Review.

18.

Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.

Panani AD.

Cancer Lett. 2007 Sep 18;255(1):12-25. Epub 2007 Mar 23. Review.

PMID:
17383090
19.

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.

Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Ruiz-Delgado GJ, Navarro-Vázquez M, González-Carrillo ML.

Rev Invest Clin. 2006 Sep-Oct;58(5):458-61.

PMID:
17408106
20.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk